Philips has announced that it has received CE marking, which allows Philips to make the Ingenuity TF PET/MR – the industry’s first commercially available, whole body PET/MR imaging system – commercially available in Europe.
The Ingenuity TF PET/MR combines the molecular imaging capabilities of PET (positron emission tomography) with the soft tissue contrast of MR (magnetic resonance) to image the disease process on a cellular level in soft tissue.
Investigators are already using the Ingenuity TF PET/MR for early diagnosis and screening in cardiology and oncology patients. For example, patients with a high-risk for heart disease are being screened to treat their diseased cells before they become dangerous coronary plaques.
The innovations that could be made possible by combining MR and PET into one whole body system opens the door for breakthroughs in early detection and personalized medicine for patients. In fact, the Ingenuity TF PET/MR was able to effectively image the prostate for the first time and detect deadly cancers in organs such as the pancreas at a significantly earlier stage.
